Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 7;26(7):107058. doi: 10.1016/j.isci.2023.107058

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Validation of predictive value of TMErisk for immunotherapy and chemotherapy in the internal cohort

(A and B) Kaplan–Meier analyses for OS and PFS based on TMErisk strata in the immunochemotherapy group from ORIENT-11 cohort.

(C) Stacked percentage bar chart shows the distribution of BOR according to TMErisk (left panel) and association of TMErisk with ORR (right panel) in the immunochemotherapy group from ORIENT-11 cohort.

(D and E) Kaplan–Meier analyses for OS and PFS based on TMErisk strata in the chemotherapy group from ORIENT-11 cohort.

(F) Stacked percentage bar chart shows the distribution of BOR according to TMErisk (left panel) and association of TMErisk with ORR (right panel) in the chemotherapy group from ORIENT-11 cohort.

(G–J) Predictive accuracy of TMErisk and PD-L1 for OS and PFS in the ORIENT-11 immunochemotherapy and chemotherapy groups. Chemo, chemotherapy; IO + Chemo, immunotherapy plus chemotherapy; HR, hazard ratio; CI, confidence interval; BOR, best overall response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; R, responder; NR, non-responder; AUC (t), time-dependent area under the receiver operating characteristic curve; OS, overall survival. See also Figure S12.